静脉血栓栓塞并发症的长期治疗和二级预防
- 作者: Petrikov A.S.1, Prostov I.I.2
-
隶属关系:
- Altai State Medical University
- Rostov State Medical University
- 期: 卷 28, 编号 4 (2020)
- 页面: 548-566
- 栏目: Reviews
- ##submission.dateSubmitted##: 23.07.2020
- ##submission.dateAccepted##: 02.11.2020
- ##submission.datePublished##: 15.12.2020
- URL: https://journals.eco-vector.com/pavlovj/article/view/40423
- DOI: https://doi.org/10.23888/PAVLOVJ2020284548-566
- ID: 40423
如何引用文章
详细
静脉血栓栓塞并发症(VTEC)是一种急性和时间有限的疾病。然而,VTEC第一次发作后的复发率很高,可能危及生命。深静脉血栓形成(DVT)和肺栓塞(PE)的发生与抗凝治疗(ACT)的应用密切相关。VTEC患者的现代临床管理的一个特点是确定ACT的持续时间。
目的:研究长期抗凝治疗和静脉血栓栓塞并发症二级预防的可能性,根据文献考虑现代药物治疗选择。
Medline和e-library 包括2020年出版物)中进行了文献检索 我们分析了随机临床和观察性研究, 与长期治疗和VTEC VKA的二级预防有关的荟萃分析, 口服抗凝剂(POAC),舒洛地昔和阿司匹林。病理生理和流行病学数据表明,经过抗凝治疗的前6个月大多数患者中,复发性VTEC的风险尚未解决。这种情况下,将抗凝药物无限期延长是有意义的。然而,长期抗凝治疗的限制因素有时是由于长期抗凝导致出血,有时导致死亡。因此,急性发作后的长期治疗时间可根据复发性静脉血栓形成和出血风险之间的平衡使用量表。近年来在VTEC的长期治疗和二级预防方面取得的主要成就已成为POAC,POAC本质上是新的和替代性的药物,使抗血栓药物库的显著扩展成为可能。同时近年来,随着一个严肃的证据基础的出现,舒洛地特已经出现在这类患者的治疗库中,其大出血和临床显著出血的发生率最低。
结果。POAC的安全性、各种药代动力学和给药方案以及近年来积极用于VTEC二级预防的舒洛地特的出现,为POAC提供了一个重要的证据基础,这将使临床医生能够对静脉血栓形成的各种临床变异采取不同的治疗方法,改善治疗结果,考虑评估个体风险和共病,考虑依从性和依从性。
全文:
![受限制的访问](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
作者简介
Alexey Petrikov
Altai State Medical University
编辑信件的主要联系方式.
Email: petricov_alex@mail.ru
ORCID iD: 0000-0002-6501-3289
SPIN 代码: 4612-6452
MD, PhD, Professor of the Department of Faculty Surgery named after Professor I.I. Neymark, Hospital Surgery with a Course of Surgery of Additional Professional Education
俄罗斯联邦, BarnaulIgor Prostov
Rostov State Medical University
Email: petricov_alex@mail.ru
ORCID iD: 0000-0002-7853-6775
SPIN 代码: 5706-3190
MD, PhD, Associate Professor of the Department of Hospital Surgery №1, Head of the Vascular Surgery Department
俄罗斯联邦, Rostov-on-Don参考
- Heit JA. Epidemiology of venous thromboembolism. Nature Reviews. Cardiology. 2015;12(8):464-74. doi: 10.1038/nrcardio.2015.83
- Bokeriya LA, Zatevakhin II, Kiriyenko AI, et al. Rossiyskiye klinicheskiye rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhneniy (VTEO). Flebologiya. 2015;9(4-2):1-52. (In Russ).
- Polikarpov AV, Aleksandrova GA, Golubev NA, et al. Obshchaya zabolevayemost’ vzroslogo naseleniya Rossii v 2017 godu. In: Statisticheskiy sbornik 2017 god. Moscow; 2018. Suppl. 4. Available at: https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisti-cheskiy-sbornik-2017-god. Accessed: 2020 July 25. (In Russ).
- Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Archives of Internal Medicine. 2000; 160(60): 761-8. doi: 10.1001/archinte.160.6.761
- Kyrle PA, Kammer M, Eischer L, et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. Journal of Thrombosis and Haemostasis. 2016;14(12):2402-9. doi: 10.1111/jth.13524
- Prandoni P, Lensing AWA, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Annals of Internal Medicine. 2002;137(12):955-60. doi: 10.7326/0003-4819-137-12-200212170-00008
- Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205. doi:10.3324/ haematol.10516
- Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376(9757):2032-9. doi: 10.1016/S0140-6736(10)60962-2
- Verso M, Agnelli G, Ageno W, et al. Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thrombosis Research. 2012;130(3):369-73. doi: 10.1016/j.thromres.2012.04.003
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2): 315-52. doi: 10.1016/j.chest.2015.11.026
- Mearns ES, Coleman CI, Patel D, et al. Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis. 2015;13(6):1043-52. doi: 10.1111/jth.12914
- Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism. Wiener Klinische Wochenschrift. 2003;115(13-14):471-4. doi: 10.1007/BF03041030
- Iorio A, Kearon C, Filippucci E, et al. Risk of
- recurrence after a first episode of symptomatic
- venous thromboembolism provoked by a transient risk factor: a systematic review. Archives of Internal Medicine. 2010;170(19):1710-6. doi: 10.1001/archinternmed.2010.367
- Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011;342:d3036. doi: 10.1136/bmj.d3036
- Kearon C, Akl EА, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 (2 suppl):e419S-94S. doi: 10.1378/chest.11-2301
- Agnelli G, Becattini C. Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism. Hematology. 2013;2013 (1):471-7. doi: 10.1182/asheducation-2013.1.471
- Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Seminars in Thrombosis and Hemostasis. 2012;38(5): 535-48. doi: 10.1055/s-0032-1315758
- Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. The American Journal of Medicine. 1993; 95(3):315-28. doi: 10.1016/0002-9343(93)90285-w
- Heit JA. Predicting the Risk of Venous Thrombo-embolism Recurrence. American Journal of Hematology. 2012;87(Suppl 1):S63-7. doi: 10.1002/ajh.23128
- Sode BF, Allin KH, Dahl M, et al. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type. CMAJ. 2013;185(5):E229-37. doi: 10.1503/cmaj.121636
- Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(Suppl 6):454S-545S. doi: 10.1378/chest.08-0658
- Kim K, Yamashita Y, Morimoto T, et al. Risk Factors for Major Bleeding during Prolonged Anticoagulation Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry. Thrombosis and Haemostasis. 2019;119(9):1498-507. doi: 10.1055/s-0039-1692425
- Kaatz S, Qureshi W, Fain C, et al. Duration of anti-coagulation treatment in patients with venous thromboembolism. The Journal of the American Osteopathic Association. 2010;110(11):638-44.
- Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-6. doi: 10.1161/CIRCULATIONAHA.109.925214
- Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417-26. doi: 10.1503/cmaj.080493
- Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of Thrombosis and Haemostasis. 2012;10(6):1019-25. doi: 10.1111/j.1538-7836.2012.04735.x
- Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012;126(4):448-54. doi: 10.1161/CIRCULATIONAHA.111.051920
- Rodger MA, Le Gal. G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:j1065. doi: 10.1136/bmj.j1065
- Kiriyenko AI, Panchenko EP, Andriyashkin VV. Venoznyy tromboz v praktike terapevta i khirurga. Moscow: Planida; 2012. (In Russ).
- Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. The New England Journal of Medicine. 2013;368(8):709-18. doi: 10.1056/NEJMoa1113697
- auersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. The New England Journal of Medicine. 2010; 363(26):2499-510. doi: 10.1056/NEJMoa1007903
- Marcucci M, Iorio A, Douketis JD, et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. Journal of Thrombosis and Haemostasis. 2015; 13(5):775-81. doi: 10.1111/jth.12871
- Jiang QJ, Bai J, Jin J, et al. Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2018;(9):876. doi: 10.3389/fphar.2018.00876.eCollection 2018
- Petrikov AS, Dudin DV, Zaitsev SV, et al. The influence of prolonged antithrombotic therapy on the development of post-thrombotic syndrome in patients with proximal deep vein thrombosis of the lower limbs. Statsionarozameshchayushchiye Tekhnologii: Ambulatornaya Khirurgiya. 2018;(3-4):83-8. doi: 10.21518/1995-1477-2018-3-4-83-88
- Petricov AS, Dudin DV, Valova OV, et al. Possibilities of long-lasting anti-thrombotic therapy in patients with proximal thrombosis of lower limbs deep veins. Vestnik SurGU. Medicina. 2018;(2):37-43. (In Russ).
- Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. The New England Journal of Medicine. 2013;368 (8):699-708. doi: 10.1056/NEJMoa1207541
- Sulodexide for the Prevention of Recurrent Venous Thromboembolism: the Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Сirculation. 2015;132(20):1891-7. doi: 10.1161/CIRCULATIONAHA.115.016930
- Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. The New England Journal of Medicine. 2012;367(21):1979-87. doi: 10.1056/NEJMoa1210384
- Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. The New England Journal of Medicine. 2013;369(15):1406-15. doi: 10.1056/NEJMoa1306638
- Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. The New England Journal of Medicine. 1999;340(12):901-7. doi: 10.1056/NEJM 199903253401201
- Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. The New England Journal of Medicine. 2003;348 (15):1425-34. doi: 10.1016/S1062-1458(03)00259-9
- Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thrombo-embolism. The New England Journal of Medicine. 2012;366(21):1959-67. doi: 10.1056/NEJMoa1114238
- Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Annals of Internal Medicine. 2003;139 (11):893-900. doi: 10.7326/0003-4819-139-11-200312020-00007
- Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. The New England Journal of Medicine. 2003;349(7): 631-9. doi: 10.1056/NEJMoa035422
- Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014; 130(13): 1062-71. doi: 10.1161/CIRCULATIONAHA.114.008828
- Pompilio G, Integlia D, Raffetto J, et al. Сomparaive Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis. TH Open. 2020;4(2):e80-e93. doi: 10.1055/s-0040-1709731
- Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines on the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2020;41(4): 543-603. doi: 10.1093/eurheartj/ehz405
- Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. The New England Journal of Medicine. 2017;376(13):1211-22. doi: 10.1056/NEJMoa1700518
- Mai V, Bertoletti L, Cucherat M, et al. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. PLoS One. 2019;14(4):e0214134. doi: 10.1371/journal.pone.0214134
补充文件
![](/img/style/loading.gif)